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Abstract 
We previously showed that mice carrying an activated Cdk4 mutation together with melanocyte-
specific mutant Hras (Cdk4R24C/R24C/TPras) develop melanoma spontaneously, but penetrance is 
increased and age of onset reduced after neonatal UVR exposure. UVR-treated mice were more 
likely to develop multiple primary lesions, and these melanomas more often expressed Trp53, and 
less often expressed c-Myc, than melanomas from non-irradiated mice (1). These data suggest 
differences in mechanisms of tumorigenesis between melanomas developing spontaneously, or as a 
result of UVR exposure. To further delineate these differences we compared global gene expression 
between spontaneous and UVR-induced melanomas from these mice using microarrays. We found 
264 genes differentially expressed between these groups (ANOVA, p<0.05). Selected candidate 
genes were validated using qRT-PCR, which confirmed upregulation of Gpr155 and Bmp7, and 
downregulation of Plagl1, Akap12 and Il18 in UVR-induced mouse melanomas. In humans, 
epidemiological studies suggest there may be two predominant pathways to melanoma 
development. One characterized by chronic UVR exposure and which leads mainly to melanomas 
on sun-exposed sites; the other associated with low UVR exposure and leading predominantly to 
melanomas on less exposed body sites. We found by immunohistochemical analysis comparing a 
series of human melanomas from the head (a chronically sun-exposed site; N=82) with a set from 
the trunk (an intermittently exposed site; N=65), that the prevalence of IL-18 expression was 
significantly lower in melanomas on the head (16%) than truncal melanomas (34%, p=0.011). We 
conclude that loss of IL-18 is a marker of UVR-induced melanoma, both in animal models and 
humans. 
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Introduction  
It is becoming evident that there are different pathways of melanoma tumorigenesis, influenced by 
different levels of ultraviolet radiation (UVR) exposure (reviewed in (2)). Melanoma development 
is strongly associated with geographical location, with incidence rates for Caucasian populations of 
17 for males and 12 for females per 100,000 in the USA, versus 39 and 30 respectively in Australia, 
and 8 and 9 respectively in the UK (3). However melanomas frequently develop on non-sun-
exposed sites and indoor workers can sometimes have higher rates of melanoma than outdoor 
workers.  
We have previously proposed a possible explanation for this paradox based on epidemiological 
studies on the population of Queensland, Australia (4). This hypothesis suggests that there may be 
two pathways or mechanisms of melanoma development that diverge after an initial UVR insult to a 
melanocyte. The first pathway is speculated to occur amongst individuals with low propensity for 
nevus development, and is characterized by heavy sun exposure. This pathway leads predominantly 
to melanomas on sun-exposed sites with TRP53 mutation or dysregulation, sun-damaged skin and 
associated keratinocyte tomors (5). The second pathway is thought to involve individuals with 
inherently higher propensity to develop nevi, and is associated with lower levels of sun-exposure 
(6). Melanomas arising through this ‘nevus prone’ pathway occur predominantly on less sun-
exposed sites. In those studies, measures of sunburn and tanning response were the same for both 
groups, supporting the proposition that other innate differences such as those controlling cell 
proliferation, apoptosis, and DNA damage repair may also be important. Recent empirical evidence 
for the divergent pathway hypothesis in humans comes from work by Maldonado et al. (7) and 
Curtin et al. (8) who found that BRAF mutations were more common in melanomas arising on 
intermittently sun-exposed sites than from elsewhere. Moreover, they found that BRAF mutations 
were rarely found in melanomas from chronically sun-exposed skin. The latter study also showed 
that other specific genomic changes, including amplifications and deletions, are selected for during 
tumorigenesis depending on whether the melanomas have arisen from chronic sun damaged skin, or 
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non-chronic sun-damaged skin (8). Together, these molecular and epidemiological studies accord 
with the proposition that melanomas arise through different pathways, depending upon the 
constitution of the host and the level of exposure to UVR. 
To explore these concepts further, we have been studying mice carrying a Cdk4 (R24C) mutation 
which prevents its binding and inhibition by p16Ink4a, together with melanocyte-specific Hras 
(G12V) (Cdk4R24C/R24C/TPras). Although these animals developed melanoma both spontaneously, 
penetrance was increased, and age of onset decreased, after neonatal UVR (1), and UVR-treated 
mice were more likely to develop multiple primary lesions. Furthermore, UVR-induced melanomas 
more often expressed Trp53, and less often expressed c-Myc (1). These results suggest differences 
in mechanisms of tumorigenesis between lesions developing spontaneously, or as a result of UVR 
exposure in this mouse model. To further elucidate these mechanistic differences we performed 
expression array analysis to compare spontaneous and UVR-induced melanomas from 
Cdk4R24C/R24C/TPras mice. We identified a number of genes that had markedly different expression 
levels between spontaneous and UVR-induced melanomas. One of these genes, Il18, was 
downregulated in UVR-induced mouse tomors. To assess whether IL-18 expression was related to 
UVR-induced melanoma development in humans we carried out an immunohistochemical study 
comparing archival tomors from body sites with markedly different levels of sun exposure. We 
found that significantly fewer human melanomas from chronic sun-exposed sites expressed IL-18. 
These data indicate that IL-18 is a novel, and robust marker of UVR-induced melanomas.  
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Materials and Methods  
Animals 
Breeding, genotyping and UVR treatment of the Cdk4R24C/R24C/TPras mice have been previously 
described (1). All experiments were undertaken with the approval of the QIMR Animal Ethics 
Committee. 
 
Processing of Tumors and RNA isolation 
Lesions were excised, and a small portion fixed for histopathological analysis. Samples used in the 
expression analyses were scored for stromal content by a pathologist (HKM). Only lesions with 
<20% stromal contamination were used. Tomors were stored at –20oC in RNAlater (Ambion, USA) 
prior to homogenization using pestles in microfuge tubes (Progen, Australia) and digestion in 
Proteinase K (Qiagen). Samples were homogenized further using a Qiagen Shredder kit (Qiagen, 
Germany). RNA was isolated using Qiagen RNeasy Mini Kits (Qiagen, Germany). RNA quantity 
and purity were determined using a Nanodrop ND-1000 spectrophotometer (Biolab, Australia) and 
Bioanalyzer 2100 (Agilent Technologies, USA).  
 
Expression Arrays 
Melanoma and universal mouse reference RNA (Stratagene, USA) was amplified using an Amino 
Allyl MessageAmp Kit (Ambion) and hybridized to mouse oligoDNA microarrays from the 
Microarray facility at the Prostate Centre, Vancouver General Hospital, Canada. These arrays 
contain 70-mer oligonucleotides representing 16,463 genes (Operon Biotechnologies, USA). 
Expression signals for each gene were determined using a G2505B microarray scanner (Agilent 
Technologies) and calculated using feature extraction 8 software (Agilent Technologies, USA). 
Data analysis was performed using GeneSpring version 7.3 software (Agilent Technologies).  
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Real-time RT-PCR 
Levels of Gpr155, Plagl1, Bmp7, Akap12, and IL18 expression were determined by SYBR Green 
(Qiagen) real-time quantitative RT-PCR (qRT-PCR). cDNA was synthesized using Superscript ΙΙ 
reverse transcriptase (Invitrogen. United Kingdom), and subsequent PCR reactions were carried out 
in a Rotorgene 6000 cycler (Corbett Research, Australia). Data was analyzed using Rotorgene 6 
software as previously described (9). Ppia (peptidylprolyl isomerase A) was selected as the 
housekeeper gene for all comparisons as it had low variation across all samples on the expression 
arrays. All primer sequences are available in Supplementary Table I. 
 
Statistical Analysis 
A one-way ANOVA t-test was used for comparisons of expression data between tumors of different 
genotypic groups (Genespring version 7.3, Agilent Technologies, USA). The Mann-Whitney U test 
was used for pairwise comparisons of qRT-PCR data (SPSS, USA).  The Chi squared test was used 
for analysis of immunohistochemical staining (Georgetown University available 
http://schnoodles.com/cgi-bin/web_chi_form.cgi).  A t-test was used for comparison of apoptosis 
rates determined by cleaved-caspase 3 positive cells. 
 
Human Melanomas and Immunohistochemical Analysis 
Our aim was to compare the prevalence of IL-18 expression in melanomas on sun-exposed and non-
exposed anatomic sites. Approval to perform the study was given by the Human Research Ethics 
Committee of the Queensland Institute of Medical Research. All participants gave their written 
consent to take part. Immunohistochemical analysis of human melanoma samples were conducted 
on a subset of participants selected from within a larger case-case comparison study of cutaneous 
melanoma. Details of subject selection and data collection for the larger study have been described 
previously (4). Briefly, potentially eligible participants were residents of greater Brisbane, Australia 
(latitude 27oS) with a histologically confirmed primary cutaneous melanoma diagnosed between 
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January 1, 1998, and December 31, 1999.  Patients were intentionally sampled within pre-defined 
strata of anatomical site of melanoma (trunk, head and neck (H&N)), age (< 50 years, >50 years) 
and sex, to explore the hypothesis that melanomas at different body sites may arise through 
different causal pathways. This series of analyses was restricted to the subset of patients diagnosed 
either with superficial spreading melanomas (SSM) of the back (n=56) or H&N (n=46), for whom 
tissue was available. Formalin-fixed paraffin-embedded tissue sections were immunostained with 
anti-interleukin 18 antibody (1/1200, MBL International, Woburn, MA) using the Vision Biosystem 
Bond auto-stainer system (Invetech, USA). Immunoreactivity was detected using NovaRed 
substrate (Vector Laboratories, USA) and counterstained with Mayers’ haematoxylin (blue), and 
scored by (HKM) (Figure 1). 147 melanomas from human patients were analysed, these included 65 
originating on the trunk (area of intermitted sun exposure) and 82 originating on the head (area of 
chronic sun exposure).  
 
Apoptosis Assay  
Melanoma cell lines were cultured in media containing RPMI 1640 (Sigma, USA), 10% fetal 
bovine serum (CSL Ltd, Australia), 200 U/ml penicillin (Gibco, USA) and 100 mg/ml streptomycin 
(Gibco). Melanoma cell lines used in this study did not express endogenous IL-18 as determined by 
analysis of Affymetrix array data previously undertaken (10), Five melanoma cell lines (A04, 
MM485, D05, MM386 and MM537) were exposed to UVB radiation (561.6 J/m2). Two hours 
before UV exposure, recombinant human IL-18 (150 ng/ml) was added to cells. The numbers of 
cleaved-caspase 3 positive cells were used as a measure of apoptosis (Supplementary figure 1). 
Cells were fixed in 100% methanol 40 h after being treated with UVR or IL-18 and UVR. Cells 
were digested in Ethanol-glacial acetic acid for 3 min and then blocked with 1% hydrogen peroxide 
0.1% sodium azide for 10 min. Sections were incubated with 10% goat serum for 20 min and anti-
cleaved caspase 3 antibody 1/100 overnight at 40C (Biocare Medical, USA). Dako Envision (Dako, 
USA) secondary antibody system was used to detect immunoactivity and color was developed using 
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Vector Red (Vector Labs). Ten representative fields were scored for the percentage of cleaved-
caspase 3-positive cells per sample.   
  
 9
Results  
Markers of UVR-induced melanoma: comparison of Cdk4R24C/R24C/TPras UVR-induced versus 
spontaneous lesions. 
The molecular differences between Cdk4R24C/R24C/TPras UVR-induced (n=4) and spontaneously 
derived (n=4) lesions were explored using gene expression arrays. The UVR-induced mouse 
melanomas developed with an earlier onset, which makes it very likely that they can be 
distinguished from those that would have developed spontaneously with later age of onset 
(Supplementary Table 2). Expression analysis using 16K mouse oligoDNA microarrays (Vancouver 
General Hospital, Canada) was performed. Parametric ANOVA test (p<0.05) identified 141 genes 
upregulated and 123 downregulated in the UVR-induced lesions when compared with the group of 
spontaneous lesions. Candidate genes for follow-up were selected based on cancer relatedness and 
fold-change. These candidate genes were further validated in a partially independent set of tumors 
using qRT-PCR (Table 1). Gpr155, (G protein-coupled receptor 155) and Bmp7 (Bone 
morphogenetic protein 7) were upregulated and Plagl1 (Pleomorphic adenoma gene 1), Akap12 (A-
kinase anchor protein 12) and Il18 (Interleukin 18) downregulated in UVR-induced lesions. 
 
IL-18 immunohistochemical analysis  
We selected IL18 as the candidate for immunohistochemical validation in human melanoma 
specimens on the basis of antibody availability and prior involvement in melanoma (11-13). It 
should be noted that commercial antibodies were not available for Gpr155, Plagl1 and Bmp7. 
Human melanomas were defined as ‘positively stained’ when >10% of melanoma cells were 
staining red in the section. The prevalence of IL-18 protein expression was significantly lower in 
melanomas arising on the head and neck (16%), compared with lesions originating from the trunk 
(34%) (Chi squared test p=0.011; Table II). 
 When analysed according to histological subtype, we found that 0 of 4 nodular melanomas and 
only 2 of 35 (5.7%) lentigo maligna melanomas (LMM) stained positively with IL-18, whereas 31 
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of 102 (30.4%) superficial spreading melanomas (SSM) and 2 of 6 (33%) unspecified melanomas 
stained positively. Because of the site predilection for LMM, we repeated the site-comparison 
analyses restricting to melanomas of the superficial spreading subtype and found that SSM of the 
head and neck remained less likely to stain positively with IL-18 (22%) than SSM of the trunk 
(38%), although this was of marginal statistical significance (p=0.085) (Table II).  
 
IL-18 regulation of apoptosis  
To assess whether IL-18 may play a role in regulation of apoptosis post-UVR, we exposed 
melanoma cell lines to UVB radiation (561.6 J/m2).  UVR treatment resulted in increased apoptosis 
in 5/5 cell lines, determined by the percent of cells expressing cleaved-caspase 3 (Figure 3).  We 
observed a significant reduction in apoptotic cells in 4/5 cell lines (A04, D05, MM386 and MM537) 
that were pre-treated with IL-18 prior to UVR exposure (t-test p<0.005).  
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Discussion  
The divergent pathway model for melanoma development suggests two mechanisms of 
tumorigenesis, one occurring in “nevus-prone” individuals and associated with lower levels of UVR 
exposure, and the second occurring in “nevus-resistant” individuals and associated with high levels 
of UVR exposure and melanomas on sun-exposed sites (4). We have found further supportive 
evidence that melanomas may arise through different pathways. In our mouse model, we validated 
five genes that were differentially expressed between UVR-induced and spontaneous melanomas. 
One of these genes, IL18 was downregulated in the UVR-induced melanomas relative to the 
spontaneous melanomas. When we examined human melanomas for IL-18 expression using 
immunohistochemistry, we found much the same pattern; melanomas from the “high level UVR” 
arm of the divergent pathway have significantly lower frequency of IL-18 expression than 
melanomas from covered areas of the body. Analysis by subtype of melanoma showed that lentigo 
melanomas, which are normally associated with chronic sun exposure, only very rarely showed 
expression of IL-18 (2/35; 5.7%).  
The role of IL18 in various aspects of tumorigenesis, including immunosuppression, angiogenesis, 
and cell proliferation, has been extensively reviewed by Vidal-Vanaclocha et al. (11).  It is not yet 
clear why IL-18 expression should be selected against during the initiation or progression of UVR-
induced melanoma.  Work by Grandjean-Laquerriere et al. has also showed enhanced IL-18 protein 
secretion following irradiation with UVB in keratinocytes (14). IL-18 can enhance the propensity of 
B16 melanoma cells to migrate (12), and it is involved in the upregulation of stem cell factor (SCF) 
(13), the c-kit ligand, in these cells. SCF itself is pivotal for regulating the activation and 
proliferation of melanocytes in response to UVR-induced skin damage (15). Our studies have 
shown IL-18 to inhibit UVB-induced apoptosis in some melanoma cell lines; work by Schwarz et 
al. has also shown this in keratinocyte cell lines (16).  Further indications of a role for IL-18 in 
UVR-induced tumorigenesis come from work on UVR-exposed mouse skin, where it can reduce the 
amount of UVR-induced DNA damage present, and consequently, photoimmunosuppression (16). 
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Injection of IL-18 into mice significantly reduced both the number of apoptotic keratinocytes and 
the amount of DNA damage present in the skin of these animals after UVR exposure. These effects 
were not observed in nucleotide excision repair (NER)-defective Xpa-null mice, indicating that Il18 
directly or indirectly enhances NER and thereby reduces the amount of UVB-induced DNA damage 
(16). The mechanism by which this pro-inflammatory cytokine affects DNA repair is unknown, but 
it shares these activities with IL-12, a related cytokine with additional shared biological properties 
(17). Il12-null mice are significantly more susceptible to UVR-induced papilloma formation than 
wildtype animals (18). The role IL18 plays in repair of UVR-induced DNA lesions is of particular 
interest, as dysfunctions of DNA repair may be a mechanism of UVR-induced melanomagenesis. 
Thus downregulation of IL-18, as was commonly seen in the chronic UVR-induced melanomas in 
this study, would be expected to elicit some suppression of DNA repair response, along with a 
degree of photo-immunosuppression that may also occur with any diminution of its role as a pro-
inflammatory cytokine.  
There is significant effort being put into investigating how IL-18 can be used for cytokine-based 
therapy for melanoma. IL-18 upregulation can inhibit tomor growth in a B16 melanoma cell 
xenograft model (19), and in a similar model it has been shown to be therapeutic in conjunction 
with X-irradiation of the induced melanomas (20). Another avenue for therapy is the use of IL-18 in 
conjuction with IL-12. This has been shown to be successful in murine melanoma models (21, 22). 
Its role in humans as a cytokine-based therapy for advanced melanoma has been reviewed by 
Atkins (23), and phase 1 clinical trials show some promise (24). 
There is now growing evidence that some somatic mutations are preferentially associated with a 
particular arm of the divergent pathway model (Figure 2), e.g. BRAF mutations are often found in 
melanomas on intermittently sun-exposed sites, but rarely on chronically exposed sites (7, 8).  
Similarly, mutations or copy number increases in c-KIT have been observed in 28% of melanomas 
on chronically sun-damaged skin, but in 0% of melanomas on skin without chronic sun damage 
(25). The addition of IL-18 to the battery of chronic UVR-induced melanoma markers further 
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highlights the possible differences between these lesions and those developing on sun-protected 
areas of the body. Moreover, IL-18 is also a candidate that may be amenable to targeted strategies 
for melanoma prevention, and treatment for a subset of melanomas.  
 
 Acknowledgements  
We are grateful to Dr Marianne Powell for the TPras mice, and Drs Marcos Malumbres and 
Mariano Barbacid for the Cdk4R24C/R24C mice. This work was funded by the Cancer Council of 
Queensland. 
 
 
 
 
 14
References 
1. Hacker, E., Muller, H. K., Irwin, N., Gabrielli, B., Lincoln, D., Pavey, S., Powell, M. B., 
Malumbres, M., Barbacid, M., Hayward, N., and Walker, G. Spontaneous and UV radiation-
induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res, 66: 
2946-2952, 2006. 
2. Rivers, J. K. Is there more than one road to melanoma? Lancet, 363: 728-730, 2004. 
3. Giblin, A. V. and Thomas, J. M. Incidence, mortality and survival in cutaneous melanoma. J 
Plast Reconstr Aesthet Surg, 60: 32-40, 2007. 
4. Whiteman, D. C., Watt, P., Purdie, D. M., Hughes, M. C., Hayward, N. K., and Green, A. C. 
Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl 
Cancer Inst, 95: 806-812, 2003. 
5. Whiteman, D. C., Parsons, P. G., and Green, A. C. p53 expression and risk factors for 
cutaneous melanoma: a case-control study. Int J Cancer, 77: 843-848, 1998. 
6. Whiteman, D. C., Stickley, M., Watt, P., Hughes, M. C., Davis, M. B., and Green, A. C. 
Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol, 24: 3172-3177, 
2006. 
7. Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., 
Albertson, D. G., Pinkel, D., and Bastian, B. C. Determinants of BRAF mutations in 
primary melanomas. J Natl Cancer Inst, 95: 1878-1890, 2003. 
8. Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K. 
H., Aiba, S., Brocker, E. B., LeBoit, P. E., Pinkel, D., and Bastian, B. C. Distinct sets of 
genetic alterations in melanoma. N Engl J Med, 353: 2135-2147, 2005. 
9. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. 
Nucleic Acids Res, 29: e45, 2001. 
10. Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., 
Boyle, G. M., Harper, U., Cozzi, S. J., Hansen, K., Yudt, L., Schmidt, C., Hersey, P., Ellem, 
K. A., O'Rourke, M. G., Parsons, P. G., Meltzer, P., Ringner, M., and Hayward, N. K. 
Microarray expression profiling in melanoma reveals a BRAF mutation signature. 
Oncogene, 23: 4060-4067, 2004. 
11. Vidal-Vanaclocha, F., Mendoza, L., Telleria, N., Salado, C., Valcarcel, M., Gallot, N., 
Carrascal, T., Egilegor, E., Beaskoetxea, J., and Dinarello, C. A. Clinical and experimental 
approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer 
Metastasis Rev, 25: 417-434, 2006. 
12. Jung, M. K., Song, H. K., Kim, K. E., Hur, D. Y., Kim, T., Bang, S., Park, H., and Cho, D. 
H. IL-18 enhances the migration ability of murine melanoma cells through the generation of 
ROI and the MAPK pathway. Immunol Lett, 107: 125-130, 2006. 
 15
13. Hue, J., Kim, A., Song, H., Choi, I., Park, H., Kim, T., Lee, W. J., Kang, H., and Cho, D. IL-
18 enhances SCF production of melanoma cells by regulating ROI and p38 MAPK activity. 
Immunol Lett, 96: 211-217, 2005. 
14. Grandjean-Laquerriere, A., Antonicelli, F., Gangloff, S. C., Guenounou, M., and Le Naour, 
R. UVB-induced IL-18 production in human keratinocyte cell line NCTC 2544 through NF-
kappaB activation. Cytokine, 37: 76-83, 2007. 
15. Kawaguchi, Y., Mori, N., and Nakayama, A. Kit(+) melanocytes seem to contribute to 
melanocyte proliferation after UV exposure as precursor cells. J Invest Dermatol, 116: 920-
925, 2001. 
16. Schwarz, A., Maeda, A., Stander, S., van Steeg, H., and Schwarz, T. IL-18 reduces 
ultraviolet radiation-induced DNA damage and thereby affects photoimmunosuppression. J 
Immunol, 176: 2896-2901, 2006. 
17. Schwarz, A., Stander, S., Berneburg, M., Bohm, M., Kulms, D., van Steeg, H., Grosse-
Heitmeyer, K., Krutmann, J., and Schwarz, T. Interleukin-12 suppresses ultraviolet 
radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol, 4: 26-31, 2002. 
18. Meeran, S. M., Mantena, S. K., Meleth, S., Elmets, C. A., and Katiyar, S. K. Interleukin-12-
deficient mice are at greater risk of UV radiation-induced skin tumors and malignant 
transformation of papillomas to carcinomas. Mol Cancer Ther, 5: 825-832, 2006. 
19. Nagai, H., Hara, I., Horikawa, T., Oka, M., Kamidono, S., and Ichihashi, M. Gene transfer 
of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo 
tumor growth through inhibition of tumor vessel formation. J Invest Dermatol, 119: 541-
548, 2002. 
20. Yang, J., Jin, G., Liu, X., and Liu, S. Therapeutic effect of pEgr-IL18-B7.2 gene 
radiotherapy in B16 melanoma-bearing mice. Hum Gene Ther, 18: 323-332, 2007. 
21. Kishida, T., Asada, H., Satoh, E., Tanaka, S., Shinya, M., Hirai, H., Iwai, M., Tahara, H., 
Imanishi, J., and Mazda, O. In vivo electroporation-mediated transfer of interleukin-12 and 
interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene 
Ther, 8: 1234-1240, 2001. 
22. Nagai, H., Hara, I., Horikawa, T., Fujii, M., Kurimoto, M., Kamidono, S., and Ichihashi, M. 
Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their 
enhancement by treatment with interleukin-18. Cancer Invest, 18: 206-213, 2000. 
23. Atkins, M. B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin 
Cancer Res, 12: 2353s-2358s, 2006. 
24. Robertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., 
Pandite, L. N., Oei, C., Kirby, L. C., Jewell, R. C., Bell, W. N., Thurmond, L. M., 
Weisenbach, J., Roberts, S., and Dar, M. M. Clinical and biological effects of recombinant 
human interleukin-18 administered by intravenous infusion to patients with advanced 
cancer. Clin Cancer Res, 12: 4265-4273, 2006. 
25. Curtin, J. A., Busam, K., Pinkel, D., and Bastian, B. C. Somatic activation of KIT in distinct 
subtypes of melanoma. J Clin Oncol, 24: 4340-4346, 2006. 
